XPEV Short Squeeze Pressure Builds as Three Signals Converge

Why this matters — Three distinct ORTEX data streams have aligned on XPEV simultaneously. Cost to borrow, utilisation, and options sentiment are all flashing elevated readings for the Chinese EV maker.

Converging Signals

Utilisation near 52-week peak. XPEV utilisation hit 95.67% on April 24. That is just 4.3 percentage points below the 52-week peak of 100%. Almost all available shares to borrow have been lent out. Short sellers are running out of inventory to establish new positions.

Cost to borrow doubles in a month. The cost to borrow stands at 1.41% APR. That is up 15.2% over the past week and up 102.5% over the past month. Rapidly rising CTB reflects tightening supply in the borrow market. It adds a direct carry cost to existing short positions.

Short interest rises as shares grow scarce. Estimated short interest reached 50.5 million shares as of April 24. That is up 17.1% over the past month. The combination of rising short interest and near-peak utilisation means short sellers are competing for a shrinking pool of lendable shares.

Options market tilts bearish. The put/call ratio is 0.54, above the 20-day average of 0.49. The PCR Z-score is 1.82. That is an elevated reading, signalling increased demand for downside protection relative to recent norms.

Corroborating Context

Analyst moves reinforce the cautious tone. Barclays lowered its price target to $16 in March while keeping an Underweight rating. Macquarie downgraded XPEV to Neutral in the same month, cutting its target from $24 to $19. The stock closed at $16.66 on April 24 — at the Barclays bear-case target. XPEV's ORTEX short score stands at 68.0 out of 100. Its utilisation ranks in the 5th percentile of its universe, meaning utilisation is exceptionally high relative to peers. EPS momentum over 30 days ranks at the 84th percentile — a rare positive signal in an otherwise pressured picture. CSOP Asset Management added 5.8 million shares in its most recent filing. Goldman Sachs trimmed 1.4 million shares over the same period.

Historical Parallel

XPEV's utilisation has previously touched 100% — its 52-week ceiling. Each time borrow supply has been fully exhausted, the CTB has also spiked. The current trajectory mirrors that setup: utilisation climbing fast in a short window, with CTB lagging slightly behind.

Data Summary

• Utilisation: 95.67% (April 24), 52-week peak 100%
• Cost to borrow: 1.41% APR, up 102.5% over past month
• Estimated short interest: 50.5 million shares, up 17.1% over past month
• Official short interest (FINRA, Apr 15): 49.1 million shares; days to cover 11.23
• Put/call ratio: 0.54 vs. 20-day average of 0.49; Z-score 1.82
• Price (Apr 24): $16.66, down 11.7% over past month
• ORTEX short score: 68.0/100
• Utilisation percentile rank: 5th (extremely high relative to peers)
• EPS momentum (30d): 84th percentile
• Recent analyst moves: Barclays PT cut to $16 (Underweight); Macquarie downgrade to Neutral, PT $19
• CSOP Asset Management added 5.8M shares in latest filing
• Goldman Sachs reduced by 1.4M shares in latest filing
• Next earnings: May 18, 2026